Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Implications and measurement of herd protection (indirect effects) for enteric vaccine development.

Wierzba TF.

Vaccine. 2019 Aug 7;37(34):4775-4777. doi: 10.1016/j.vaccine.2019.02.061.

2.

A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children.

Raqib R, Sarker P, Zaman K, Alam NH, Wierzba TF, Maier N, Talukder K, Baqui AH, Suvarnapunya AE, Qadri F, Walker RI, Fix A, Venkatesan MM.

Hum Vaccin Immunother. 2019;15(6):1326-1337. doi: 10.1080/21645515.2019.1575165. Epub 2019 Mar 19.

PMID:
30794051
3.

The global burden of enteric fevers in the age of typhoid-conjugate vaccines.

Wierzba TF, Sanders JW.

Lancet Infect Dis. 2019 Apr;19(4):340-341. doi: 10.1016/S1473-3099(19)30064-7. Epub 2019 Feb 18. No abstract available.

4.

Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.

Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A.

Vaccine. 2019 Sep 3;37(37):5645-5656. doi: 10.1016/j.vaccine.2018.11.040. Epub 2018 Nov 22.

5.

Hepatitis E infection in Odisha, India: A descriptive analysis.

Kar SK, Dwibedi B, Mogasale VV, Sabat J, Mogasale V, Wierzba TF.

Indian J Public Health. 2018 Jul-Sep;62(3):231-234. doi: 10.4103/ijph.IJPH_46_17.

6.

Oral cholera vaccines and their impact on the global burden of disease.

Wierzba TF.

Hum Vaccin Immunother. 2019;15(6):1294-1301. doi: 10.1080/21645515.2018.1504155. Epub 2018 Oct 12.

7.

Estimating Typhoid Fever Risk Associated with Lack of Access to Safe Water: A Systematic Literature Review.

Mogasale VV, Ramani E, Mogasale V, Park JY, Wierzba TF.

J Environ Public Health. 2018 Jul 4;2018:9589208. doi: 10.1155/2018/9589208. eCollection 2018.

8.

Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease.

Jeon HJ, Pak GD, Im J, Owusu-Dabo E, Adu-Sarkodie Y, Gassama Sow A, Bassiahi Soura A, Gasmelseed N, Keddy KH, Bjerregaard-Andersen M, Konings F, Aseffa A, Crump JA, Chon Y, Breiman RF, Park SE, Cruz Espinoza LM, Seo HJ, May J, Meyer CG, Andrews JR, Panzner U, von Kalckreuth V, Wierzba TF, Rakotozandrindrainy R, Dougan G, Levine MM, Hombach J, Kim JH, Clemens JD, Baker S, Marks F.

Clin Infect Dis. 2018 Nov 28;67(12):1824-1830. doi: 10.1093/cid/ciy386.

9.

Antibody secreting B cells and plasma antibody response to rotavirus vaccination in infants from Kolkata India.

Sinha A, Kanungo S, Kim DR, Manna B, Song M, Park JY, Haldar B, Sharma P, Mallick AH, Kim SA, Babji S, Sur D, Kang G, Ali M, Petri WA Jr, Wierzba TF, Czerkinsky C, Nandy RK, Dey A.

Heliyon. 2018 Feb 1;4(1):e00519. doi: 10.1016/j.heliyon.2018.e00519. eCollection 2018 Jan.

10.

Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.

Qadri F, Ali M, Lynch J, Chowdhury F, Khan AI, Wierzba TF, Excler JL, Saha A, Islam MT, Begum YA, Bhuiyan TR, Khanam F, Chowdhury MI, Khan IA, Kabir A, Riaz BK, Akter A, Khan A, Asaduzzaman M, Kim DR, Siddik AU, Saha NC, Cravioto A, Singh AP, Clemens JD.

Lancet Infect Dis. 2018 Jun;18(6):666-674. doi: 10.1016/S1473-3099(18)30108-7. Epub 2018 Mar 14.

11.

Exploring the broader consequences of diarrhoeal diseases on child health.

Wierzba TF, Muhib F.

Lancet Glob Health. 2018 Mar;6(3):e230-e231. doi: 10.1016/S2214-109X(18)30047-0. No abstract available.

12.

Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference.

Walker RI, Wierzba TF, Mani S, Bourgeois AL.

Vaccine. 2017 Dec 14;35(49 Pt A):6775-6782. doi: 10.1016/j.vaccine.2017.09.045. Epub 2017 Oct 4.

13.

Erratum to: A systematic review of the epidemiology of hepatitis E virus in Africa.

Kim JH, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF.

BMC Infect Dis. 2017 Mar 3;17(1):187. doi: 10.1186/s12879-017-2274-3. No abstract available.

14.

Influence of maternal and socioeconomic factors on breast milk fatty acid composition in urban, low-income families.

Nayak U, Kanungo S, Zhang D, Ross Colgate E, Carmolli MP, Dey A, Alam M, Manna B, Nandy RK, Kim DR, Paul DK, Choudhury S, Sahoo S, Harris WS, Wierzba TF, Ahmed T, Kirkpatrick BD, Haque R, Petri WA Jr, Mychaleckyj JC.

Matern Child Nutr. 2017 Oct;13(4). doi: 10.1111/mcn.12423. Epub 2017 Feb 15.

15.

Comparison of IPV to tOPV week 39 boost of primary OPV vaccination in Indian infants: an open labelled randomized controlled trial.

Kanungo S, Kim DR, Haldar B, Snider C, Nalavade U, Kim SA, Park JY, Sinha A, Mallick AH, Manna B, Sur D, Nandy RK, Deshpande JM, Czerkinsky C, Wierzba TF, Petri WA Jr, Ali M, Dey A.

Heliyon. 2017 Jan 9;3(1):e00223. doi: 10.1016/j.heliyon.2016.e00223. eCollection 2017 Jan.

16.

Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study.

Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb MA, Ali M, Aseffa A, Baker S, Biggs HM, Bjerregaard-Andersen M, Breiman RF, Campbell JI, Cosmas L, Crump JA, Espinoza LM, Deerin JF, Dekker DM, Fields BS, Gasmelseed N, Hertz JT, Van Minh Hoang N, Im J, Jaeger A, Jeon HJ, Kabore LP, Keddy KH, Konings F, Krumkamp R, Ley B, Løfberg SV, May J, Meyer CG, Mintz ED, Montgomery JM, Niang AA, Nichols C, Olack B, Pak GD, Panzner U, Park JK, Park SE, Rabezanahary H, Rakotozandrindrainy R, Raminosoa TM, Razafindrabe TJ, Sampo E, Schütt-Gerowitt H, Sow AG, Sarpong N, Seo HJ, Sooka A, Soura AB, Tall A, Teferi M, Thriemer K, Warren MR, Yeshitela B, Clemens JD, Wierzba TF.

Lancet Glob Health. 2017 Mar;5(3):e310-e323. doi: 10.1016/S2214-109X(17)30022-0.

17.

Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016.

Wierzba TF, Bourgis A; Steering Committee for Development of a Diarrhea Severity Scale.

Vaccine. 2017 Jan 23;35(4):503-507. doi: 10.1016/j.vaccine.2016.12.006. Epub 2016 Dec 26.

PMID:
28034476
18.

Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.

Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Asaduzzaman M, Akter A, Khan A, Begum YA, Bhuiyan TR, Khanam F, Chowdhury MI, Islam T, Chowdhury AI, Rahman A, Siddique SA, You YA, Kim DR, Siddik AU, Saha NC, Kabir A, Cravioto A, Desai SN, Singh AP, Clemens JD.

N Engl J Med. 2016 May 5;374(18):1723-32. doi: 10.1056/NEJMoa1510330.

19.

Impact of oral cholera vaccines in cholera-endemic countries: A mathematical modeling study.

Kim JH, Mogasale V, Burgess C, Wierzba TF.

Vaccine. 2016 Apr 19;34(18):2113-20. doi: 10.1016/j.vaccine.2016.03.004. Epub 2016 Mar 15.

PMID:
26993337
20.

Status of vaccine research and development for enterotoxigenic Escherichia coli.

Bourgeois AL, Wierzba TF, Walker RI.

Vaccine. 2016 Jun 3;34(26):2880-2886. doi: 10.1016/j.vaccine.2016.02.076. Epub 2016 Mar 15.

21.

The Typhoid Fever Surveillance in Africa Program (TSAP): Clinical, Diagnostic, and Epidemiological Methodologies.

von Kalckreuth V, Konings F, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, Baker S, Breiman RF, Bjerregaard-Andersen M, Clemens JD, Crump JA, Cruz Espinoza LM, Deerin JF, Gasmelseed N, Sow AG, Im J, Keddy KH, Cosmas L, May J, Meyer CG, Mintz ED, Montgomery JM, Olack B, Pak GD, Panzner U, Park SE, Rakotozandrindrainy R, Schütt-Gerowitt H, Soura AB, Warren MR, Wierzba TF, Marks F.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S9-S16. doi: 10.1093/cid/civ693.

22.

Validation and Identification of Invasive Salmonella Serotypes in Sub-Saharan Africa by Multiplex Polymerase Chain Reaction.

Al-Emran HM, Krumkamp R, Dekker DM, Eibach D, Aaby P, Adu-Sarkodie Y, Ali M, Rubach MP, Bjerregaard-Andersen M, Crump JA, Cruz Espinoza LM, Løfberg SV, Gassama Sow A, Hertz JT, Im J, Jaeger A, Kabore LP, Konings F, Meyer CG, Niang A, Pak GD, Panzner U, Park SE, Rabezanahary H, Rakotozandrindrainy R, Raminosoa TM, Razafindrabe TJ, Sampo E, Schütt-Gerowitt H, Sarpong N, Soura AB, Tall A, von Kalckreuth V, Wierzba TF, May J, Marks F.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S80-2. doi: 10.1093/cid/civ782.

PMID:
26933026
23.

Utilization of Healthcare in the Typhoid Fever Surveillance in Africa Program.

Panzner U, Pak GD, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, Baker S, Bjerregaard-Andersen M, Crump JA, Deerin J, Cruz Espinoza LM, Gasmelseed N, Heriniaina JN, Hertz JT, Im J, von Kalckreuth V, Keddy KH, Lankoande B, Løfberg S, Meyer CG, Oresto MM, Park JK, Park SE, Rakotozandrindrainy R, Sarpong N, Soura AB, Gassama Sow A, Tall A, Teferi M, Worku A, Yeshitela B, Wierzba TF, Marks F.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S56-68. doi: 10.1093/cid/civ891.

24.

Prevalence of Salmonella Excretion in Stool: A Community Survey in 2 Sites, Guinea-Bissau and Senegal.

Im J, Nichols C, Bjerregaard-Andersen M, Sow AG, Løfberg S, Tall A, Pak GD, Aaby P, Baker S, Clemens JD, Espinoza LM, Konings F, May J, Monteiro M, Niang A, Panzner U, Park SE, Schütt-Gerowitt H, Wierzba TF, Marks F, von Kalckreuth V.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S50-5. doi: 10.1093/cid/civ789.

25.

A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa.

Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, Bjerregaard-Andersen M, Breiman RF, Clemens JD, Crump JA, Cruz Espinoza LM, Deerin J, Dekker DM, Gassama Sow A, Hertz JT, Im J, Ibrango S, von Kalckreuth V, Kabore LP, Konings F, Løfberg SV, Meyer CG, Mintz ED, Montgomery JM, Olack B, Pak GD, Panzner U, Park SE, Razafindrabe JL, Rabezanahary H, Rakotondrainiarivelo JP, Rakotozandrindrainy R, Raminosoa TM, Schütt-Gerowitt H, Sampo E, Soura AB, Tall A, Warren M, Wierzba TF, May J, Marks F.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S42-6. doi: 10.1093/cid/civ788.

26.

The Emergence of Reduced Ciprofloxacin Susceptibility in Salmonella enterica Causing Bloodstream Infections in Rural Ghana.

Eibach D, Al-Emran HM, Dekker DM, Krumkamp R, Adu-Sarkodie Y, Cruz Espinoza LM, Ehmen C, Boahen K, Heisig P, Im J, Jaeger A, von Kalckreuth V, Pak GD, Panzner U, Park SE, Reinhardt A, Sarpong N, Schütt-Gerowitt H, Wierzba TF, Marks F, May J.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S32-6. doi: 10.1093/cid/civ757.

PMID:
26933017
27.

The Relationship Between Invasive Nontyphoidal Salmonella Disease, Other Bacterial Bloodstream Infections, and Malaria in Sub-Saharan Africa.

Park SE, Pak GD, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, Biggs HM, Bjerregaard-Andersen M, Breiman RF, Crump JA, Cruz Espinoza LM, Eltayeb MA, Gasmelseed N, Hertz JT, Im J, Jaeger A, Parfait Kabore L, von Kalckreuth V, Keddy KH, Konings F, Krumkamp R, MacLennan CA, Meyer CG, Montgomery JM, Ahmet Niang A, Nichols C, Olack B, Panzner U, Park JK, Rabezanahary H, Rakotozandrindrainy R, Sampo E, Sarpong N, Schütt-Gerowitt H, Sooka A, Soura AB, Sow AG, Tall A, Teferi M, Yeshitela B, May J, Wierzba TF, Clemens JD, Baker S, Marks F.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S23-31. doi: 10.1093/cid/civ893.

28.

Variations of Invasive Salmonella Infections by Population Size in Asante Akim North Municipal, Ghana.

Cruz Espinoza LM, Nichols C, Adu-Sarkodie Y, Al-Emran HM, Baker S, Clemens JD, Dekker DM, Eibach D, Krumkamp R, Boahen K, Im J, Jaeger A, von Kalckreuth V, Pak GD, Panzner U, Park SE, Park JK, Sarpong N, Schütt-Gerowitt H, Toy T, Wierzba TF, Marks F, May J.

Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S17-22. doi: 10.1093/cid/civ787.

PMID:
26933015
29.

Revisiting typhoid fever surveillance in low and middle income countries: lessons from systematic literature review of population-based longitudinal studies.

Mogasale V, Mogasale VV, Ramani E, Lee JS, Park JY, Lee KS, Wierzba TF.

BMC Infect Dis. 2016 Jan 29;16:35. doi: 10.1186/s12879-016-1351-3. Review.

30.

Use of the data system for field management of a clinical study conducted in Kolkata, India.

Park JY, Kim DR, Haldar B, Mallick AH, Kim SA, Dey A, Nandy RK, Paul DK, Choudhury S, Sahoo S, Wierzba TF, Sur D, Kanungo S, Ali M, Manna B.

BMC Res Notes. 2016 Jan 9;9:20. doi: 10.1186/s13104-015-1767-7.

31.

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus.

Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C.

PLoS One. 2016 Jan 5;11(1):e0146010. doi: 10.1371/journal.pone.0146010. eCollection 2016.

32.

Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design.

Ali M, You YA, Sur D, Kanungo S, Kim DR, Deen J, Lopez AL, Wierzba TF, Bhattacharya SK, Clemens JD.

Vaccine. 2016 Jan 20;34(4):479-485. doi: 10.1016/j.vaccine.2015.12.004. Epub 2015 Dec 17.

PMID:
26707378
33.

Bloodstream Infections and Frequency of Pretreatment Associated With Age and Hospitalization Status in Sub-Saharan Africa.

Nichols C, Cruz Espinoza LM, von Kalckreuth V, Aaby P, Ahmed El Tayeb M, Ali M, Aseffa A, Bjerregaard-Andersen M, Breiman RF, Cosmas L, Crump JA, Dekker DM, Gassama Sow A, Gasmelseed N, Hertz JT, Im J, Kabore LP, Keddy KH, Konings F, Valborg Løfberg S, Meyer CG, Montgomery JM, Niang A, Njariharinjakamampionona A, Olack B, Pak GD, Panzner U, Park JK, Park SE, Rabezanahary H, Rakotondrainiarivelo JP, Rakotozandrindrainy R, Raminosoa TM, Rubach MP, Teferi M, Seo HJ, Sooka A, Soura A, Tall A, Toy T, Yeshitela B, Clemens JD, Wierzba TF, Baker S, Marks F.

Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S372-9. doi: 10.1093/cid/civ730.

34.

Assessing different measures of population-level vaccine protection using a case-control study.

Ali M, You YA, Kanungo S, Manna B, Deen JL, Lopez AL, Wierzba TF, Bhattacharya SK, Sur D, Clemens JD.

Vaccine. 2015 Nov 27;33(48):6878-83. doi: 10.1016/j.vaccine.2015.07.045. Epub 2015 Sep 9.

PMID:
26364121
35.

An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India.

Mogasale V, Kar SK, Kim JH, Mogasale VV, Kerketta AS, Patnaik B, Rath SB, Puri MK, You YA, Khuntia HK, Maskery B, Wierzba TF, Sah B.

PLoS Negl Trop Dis. 2015 Sep 9;9(9):e0004072. doi: 10.1371/journal.pntd.0004072. eCollection 2015.

36.

Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand.

Ratanasuwan W, Kim YH, Sah BK, Suwanagool S, Kim DR, Anekthananon A, Lopez AL, Techasathit W, Grahek SL, Clemens JD, Wierzba TF.

Vaccine. 2015 Sep 11;33(38):4820-6. doi: 10.1016/j.vaccine.2015.07.073. Epub 2015 Aug 1.

PMID:
26241948
37.

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.

Desai SN, Akalu Z, Teshome S, Teferi M, Yamuah L, Kim DR, Yang JS, Hussein J, Park JY, Jang MS, Mesganaw C, Taye H, Beyene D, Bedru A, Singh AP, Wierzba TF, Aseffa A.

Am J Trop Med Hyg. 2015 Sep;93(3):527-533. doi: 10.4269/ajtmh.14-0683. Epub 2015 Jun 15.

38.

An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.

Kanungo S, Desai SN, Saha J, Nandy RK, Sinha A, Kim DR, Bannerjee B, Manna B, Yang JS, Ali M, Sur D, Wierzba TF.

PLoS Negl Trop Dis. 2015 May 29;9(5):e0003809. doi: 10.1371/journal.pntd.0003809. eCollection 2015 May.

39.

Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India.

Wierzba TF, Kar SK, Mogasale VV, Kerketta AS, You YA, Baral P, Khuntia HK, Ali M, Kim YH, Rath SB, Bhattachan A, Sah B.

Vaccine. 2015 May 15;33(21):2463-9. doi: 10.1016/j.vaccine.2015.03.073. Epub 2015 Apr 4.

40.

Vaccine introduction in the Democratic People's Republic of Korea.

Marks F, Nyambat B, Xu ZY, von Kalckreuth V, Kilgore PE, Seo HJ, Du Y, Park SE, Im J, Konings F, Meyer CG, Wierzba TF, Clemens JD.

Vaccine. 2015 May 11;33(20):2297-300. doi: 10.1016/j.vaccine.2015.03.005. Epub 2015 Mar 10.

PMID:
25769209
41.

Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.

Kanungo S, Desai SN, Nandy RK, Bhattacharya MK, Kim DR, Sinha A, Mahapatra T, Yang JS, Lopez AL, Manna B, Bannerjee B, Ali M, Dhingra MS, Chandra AM, Clemens JD, Sur D, Wierzba TF.

PLoS Negl Trop Dis. 2015 Mar 12;9(3):e0003574. doi: 10.1371/journal.pntd.0003574. eCollection 2015 Mar.

42.

Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India.

Kar SK, Pach A, Sah B, Kerketta AS, Patnaik B, Mogasale V, Kim YH, Rath SB, Shin S, Khuntia HK, Bhattachan A, Puri MK, Wierzba TF, Kaljee LM.

Hum Vaccin Immunother. 2014;10(10):2834-42. doi: 10.4161/21645515.2014.971655.

43.

Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment.

Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, Kim YE, Park JK, Wierzba TF.

Lancet Glob Health. 2014 Oct;2(10):e570-80. doi: 10.1016/S2214-109X(14)70301-8. Erratum in: Lancet Glob Health. 2014 Dec;2(12):e696.

44.

The epidemiological and clinical characteristics of diarrhea associated with enteropathogenic, enteroaggregative and diffuse-adherent Escherichia coli in Egyptian children.

Ahmed SF, Shaheen HI, Abdel-Messih IA, Mostafa M, Putnam SD, Kamal KA, Sayed AN, Frenck RW Jr, Sanders JW, Klena JD, Wierzba TF.

J Trop Pediatr. 2014 Oct;60(5):397-400. doi: 10.1093/tropej/fmu034. Epub 2014 Aug 13.

PMID:
25122630
45.

A systematic review of the epidemiology of hepatitis E virus in Africa.

Kim JH, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF.

BMC Infect Dis. 2014 Jun 5;14:308. doi: 10.1186/1471-2334-14-308. Review. Erratum in: BMC Infect Dis. 2017 Mar 3;17 (1):187.

46.

Little evidence of subclinical avian influenza virus infections among rural villagers in Cambodia.

Gray GC, Krueger WS, Chum C, Putnam SD, Wierzba TF, Heil GL, Anderson BD, Yasuda CY, Williams M, Kasper MR, Saphonn V, Blair PJ.

PLoS One. 2014 May 12;9(5):e97097. doi: 10.1371/journal.pone.0097097. eCollection 2014.

47.

Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: a systematic literature review.

Mogasale V, Desai SN, Mogasale VV, Park JK, Ochiai RL, Wierzba TF.

PLoS One. 2014 Apr 17;9(4):e93784. doi: 10.1371/journal.pone.0093784. eCollection 2014. Review.

48.

Socio-ecological risk factors for prime-age adult death in two coastal areas of Vietnam.

Kim DR, Ali M, Thiem VD, Wierzba TF.

PLoS One. 2014 Feb 26;9(2):e89780. doi: 10.1371/journal.pone.0089780. eCollection 2014.

49.

Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.

Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, Bhattachan A, You YA, Puri MK, Lopez AL, Maskery B, Nair GB, Clemens JD, Wierzba TF.

PLoS Negl Trop Dis. 2014 Feb 6;8(2):e2629. doi: 10.1371/journal.pntd.0002629. eCollection 2014 Feb.

50.

Strategy, demand, management, and costs of an international cholera vaccine stockpile.

Maskery B, DeRoeck D, Levin A, Kim YE, Wierzba TF, Clemens JD.

J Infect Dis. 2013 Nov 1;208 Suppl 1:S15-22. doi: 10.1093/infdis/jit233. Review.

PMID:
24101640

Supplemental Content

Loading ...
Support Center